Free Trial

Pieris Pharmaceuticals Q4 2023 Earnings Report

Pieris Pharmaceuticals logo
$13.60 -2.53 (-15.69%)
(As of 12/13/2024)

Pieris Pharmaceuticals EPS Results

Actual EPS
-$4.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pieris Pharmaceuticals Revenue Results

Actual Revenue
$1.30 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pieris Pharmaceuticals Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Register for the FREE Workshop Now & get $10 in Bitcoin

Pieris Pharmaceuticals Earnings Headlines

One new option listing and one option delisting on December 16th
Crypto’s hidden gem + greatest crypto bull run in history = $$$?
You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss.
See More Pieris Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pieris Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pieris Pharmaceuticals and other key companies, straight to your email.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals (NASDAQ:PIRS), a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

View Pieris Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Upcoming Earnings